IgA nephropathy: an overview of drug treatments in clinical trials

References

• Roberts ISD. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014 Aug;10(8):445–454.
   PubMed Web of Science ®Google Scholar
• Radford MG, Donadio JV, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy. JASN. 1997;8(2):199–207. -02-01 00:00:00.
   Web of Science ®Google Scholar
• D’Amico G, Colasanti G, Barbiano Di Belgioioso G, et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol. 1987 Dec;7(4):355–358.
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007 12;18(12):3177–3183.
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Shi S, Twaij S, et al. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol. 2020;11:572754.
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Cheung CK, Muto M, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019 05;23(5):577–588.
   PubMed Web of Science ®Google Scholar
• Lai KN. Pathogenesis of IgA nephropathy. Nat Rev Nephrol. 2012 Mar 20; 8(5):275–283.
   PubMed Web of Science ®Google Scholar
• Barratt J, Smith AC, Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton). 2007 Jun;12(3):275–284.
   PubMed Web of Science ®Google Scholar
• Novak J, Julian BA, Tomana M, et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008 01;28(1):78–87.
   PubMed Web of Science ®Google Scholar
• Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012 09; 23(9): 1579–1587.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014 10; 18(5): 770–777.
   PubMed Web of Science ®Google Scholar
• Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104(1):73–81.
   PubMed Web of Science ®Google Scholar
• Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol. 1998 11; 9(11): 2048–2054.
   PubMed Web of Science ®Google Scholar
• Lechner SM, Papista C, Chemouny JM, et al. Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol. 2016 02; 29(1): 5–11.
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Cheung CK, Barratt J. Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link. Journal of Immunogenetics. 2022 Feb;49(1):8–21.
   Google Scholar
• Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001 09; 60(3): 969–973.
   PubMed Web of Science ®Google Scholar
• Tortajada A, Gutierrez E, Pickering MC, et al. The role of complement in IgA nephropathy. Mol Immunol. 2019 10;114:123–132.
   PubMed Web of Science ®Google Scholar
• Bene MC, Faure GC. Composition of mesangial deposits in IgA nephropathy: complement factors. Nephron. 1987;46(2):219.
   PubMed Web of Science ®Google Scholar
• Waldherr R, Seelig HP, Rambausek M, et al. Deposition of polymeric IgA1 in idiopathic mesangial IgA-glomerulonephritis. Klin Wochenschr. 1983 Sep 15;61(18):911–915.
   PubMedGoogle Scholar
• Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant. 2007 11; 22(11): 3191–3195.
   PubMed Web of Science ®Google Scholar
• Oortwijn BD, van der Boog PJM, Roos A, et al. A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int. 2006 Apr 1 69(7):1131–1138.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu L, Liu G, et al. The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrol Dial Transplant. 2008 01; 23(1): 207–212.
   PubMed Web of Science ®Google Scholar
• Kerr MA. The structure and function of human IgA. Biochem J. 1990 Oct 15;271(2):285–296.
   PubMed Web of Science ®Google Scholar
• Barratt J, Smith AC, Molyneux K, et al. Immunopathogenesis of IgAN. Semin Immunopathol. 2007 11;29(4):427–443.
   PubMed Web of Science ®Google Scholar
• Emmerson CD, EJvd V, Braam MR, et al. Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. PLOS ONE. 2011 14 Oct 6(10):e26299.
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402–2414.
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, A Inker L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019 Mar 7, 14(3):469–481.
   PubMed Web of Science ®Google Scholar
• Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Diseases. 2016;68(3):392–401.
   PubMed Web of Science ®Google Scholar
• Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. JASN. 2019;30(9):1735–1745.
   Web of Science ®Google Scholar
• Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019 09;30(9):1746–1755.
   PubMed Web of Science ®Google Scholar
• KDIGO. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012 June;2(2):209–217.
   Web of Science ®Google Scholar
• Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225.
   PubMed Web of Science ®Google Scholar
• Goodwin JE. Role of the glucocorticoid receptor in glomerular disease. Am J Physiol Renal Physiol. 2019 Jul 1,;317(1):F133–F136.
   PubMed Web of Science ®Google Scholar
• Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol. 1978;62(3):162–166.
   PubMed Web of Science ®Google Scholar
• Cupps TR, Gerrard TL, Falkoff RJM, et al. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest. 1985;75(2):754–761.
   PubMed Web of Science ®Google Scholar
• Förster A, Emmler T, Schwalm S, et al. Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1-phosphate. Kidney Int. 2010 May 2 77(10):870–879.
   PubMed Web of Science ®Google Scholar
• Kuriki M, Asahi K, Asano K, et al. Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy. Nephrology, dialysis, transplantation. 2003 Jul;18(7):1311–1315.
   PubMed Web of Science ®Google Scholar
• de Haij S, Daha MR, Kooten C. Mechanism of steroid action in renal epithelial cells. Kidney Int. 2004 May;65(5):1577–1588.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017 Nov;39(11):2216–2229.
   PubMed Web of Science ®Google Scholar
• Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999 Mar 13;353(9156):883–887.
   PubMed Web of Science ®Google Scholar
• Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009 12; 24(12): 3694–3701.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009 01;53(1):26–32.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 july 01;318(5):432–442.
   PubMed Web of Science ®Google Scholar
• Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020 Oct;98(4):1044–1052.
   PubMed Web of Science ®Google Scholar
• Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022 May 17;327(19):1888–1898.
   PubMed Web of Science ®Google Scholar
• Beckwith H, Medjeral-Thomas N, Galliford J, et al. Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrol Dial Transplant. 2017 Jan 01;32(suppl_1):i123–i128.
   PubMedGoogle Scholar
• Shen X, Liang S, Chen H, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015 Aug;28(4):441–449.
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014 Oct;86(4):828–836.
   PubMed Web of Science ®Google Scholar
• Haas M, Verhave JC, Liu Z, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):691–701.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017 May;91(5):1014–1021.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534–545.
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Dillon M, Barratt J. IgA nephropathy: driving innovation with a rare renal disease registry. Journal of Kidney Care. 2017 July 2; 2(4):205–211.
   Google Scholar
• Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(3_suppl):2–8.
   PubMed Web of Science ®Google Scholar
• Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Diseases. 2015;66(5):783–791.
   PubMed Web of Science ®Google Scholar
• Hou J, Le W, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Diseases. 2017;69(6):788–795.
   PubMed Web of Science ®Google Scholar
• Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78(4):661–671.
   PubMed Web of Science ®Google Scholar
• Mejia JC, Basu A, Shapiro R. Chapter 17 - Calcineurin inhibitors. Kidney transplantation. Seventh Edition ed. Philadelphia, USA: Elsevier Inc; 2014. 231–249.
   Google Scholar
• Escolano A, Martínez-Martínez S, Alfranca A, et al. Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38. EMBO J. 2014 May 16, 33(10):1117–1133.
   PubMed Web of Science ®Google Scholar
• Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159(2):199–207.
   PubMed Web of Science ®Google Scholar
• Kim Y, Chin HJ, Koo HS, et al. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS ONE. 2013;8(8):e71545.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000 Nov;59(11):841–849.
   PubMed Web of Science ®Google Scholar
• Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis. 1999 06; 33(6): 1049–1057.
   PubMed Web of Science ®Google Scholar
• McCarthy DD, Kujawa J, Wilson C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011 Oct;121(10):3991–4002.
   PubMed Web of Science ®Google Scholar
• Chemouny JM, Gleeson PJ, Abbad L, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol Dial Transplant. 2019 Jul 01;34(7):1135–1144.
   PubMed Web of Science ®Google Scholar
• Di Leo V, Gleeson PJ, Sallustio F, et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model. J Pers Med. 2021 Apr 16 11(4):309.
   PubMed Web of Science ®Google Scholar
• De Angelis M, Montemurno E, Piccolo M, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PloS one. 2014;9(6):e99006.
   PubMed Web of Science ®Google Scholar
• Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014 11; 46(11): 1187–1196.
   PubMed Web of Science ®Google Scholar
• Mei HE, Frölich D, Giesecke C, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010 December 9 116(24):5181–5190.
   PubMed Web of Science ®Google Scholar
• Smerud HK, Bárány P, Lindström K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011 10; 26(10): 3237–3242.
   PubMed Web of Science ®Google Scholar
• Molyneux K, Wimbury D, Barratt J. P0344nefecon® (Budesonide) selectively reduces circulating levels of baff (Blys) and soluble bcma and taci in iga nephropathy. Nephrology, dialysis, transplantation. 2020 Jun 1;35(Supplement_3):iii648.
   PubMedGoogle Scholar
• Molyneux K, Scionti K, Wolski W, et al. FC050: nefecon®. Selectively Modifies the Composition of Circulating Immune Complexes in IGA Nephropathy. Nephrology, dialysis, transplantation 2022 May 3;37(Supplement_3):i815–i817.
   Google Scholar
• Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 may 27;389(10084):2117–2127.
   PubMed Web of Science ®Google Scholar
• BARRATT J, Stone A, Kristensen J. POS-830 nefecon for the treatment of IgA nephropathy in patients at risk of progressing to end-stage renal disease: the nefigard phase 3 trial results. Kidney Int Rep. 2021 Apr;6(4):S361.
   Google Scholar
• Zhao J, Bai M, Yang X, et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Ren Fail. 2021 Jan 1 43(1):928–933.
   PubMed Web of Science ®Google Scholar
• Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012 Oct 1, 82(7):790–796.
   PubMed Web of Science ®Google Scholar
• Shimozato S, Hiki Y, Odani H, et al. Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transplant. 2008 Jun;23(6):1931–1939.
   PubMed Web of Science ®Google Scholar
• Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002 Nov;13(2):S3–S10.
   PubMedGoogle Scholar
• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019 Jul 04;381(1):36–46.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012 04; 64(4): 1215–1226.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. JASN. 2017;28(4):1306–1313. -04-01 00:00:00.
   Web of Science ®Google Scholar
• Dwivedi S, Rendón-Huerta EP, Ortiz-Navarrete V, et al. CD38 and regulation of the immune response cells in cancer. J Oncol. 2021 Feb 27;2021:6630295–11.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Boxhammer R, Thakur A, et al. Immunologic responses after COVID-19 vaccination in patients with membranous nephropathy receiving anti–CD38 felzartamab therapy: results from the phase 1b/2a M-PLACE study. Kidney Int Rep. 2022 Sep;7(9):2086–2090.
   PubMed Web of Science ®Google Scholar
• Tian M, Luan J, Jiao C, et al. Co-occurrence of IgA nephropathy and IgG4-tubulointersitial nephritis effectively treated with tacrolimus: a case report. BMC Nephrol. 2021 Aug 12, 22(1):279.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Zhao P, et al. Functional implications of regulatory B cells in human IgA nephropathy. Scand J Immunol. 2014 Jan;79(1):51–60.
   PubMed Web of Science ®Google Scholar
• Zachova K, Jemelkova J, Kosztyu P, et al. Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors. J Am Soc Nephrol. 2022 Feb 3 33(5):908–917.
   PubMed Web of Science ®Google Scholar
• Raab MS, Engelhardt M, Blank A, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. Lancet Haematol. 2020 May;7(5):e381–e394.
   PubMed Web of Science ®Google Scholar
• Abadier M, Estevam J, Berg D, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020 Nov 5; 136(Supplement 1):9.
   Google Scholar
• MacLennan I, Vinuesa C. Dendritic cells, BAFF, and april: innate players in adaptive antibody responses. Immunity. 2002 09;17(3):235–238.
   PubMed Web of Science ®Google Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and April. Nat Immunol. 2002 09; 3(9): 822–829.
   PubMed Web of Science ®Google Scholar
• Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26(1):261–292.
   PubMedGoogle Scholar
• Xin G, Shi W, Xu L, et al. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2013 Jul;26(4):683–690.
   PubMed Web of Science ®Google Scholar
• Sallustio F, Curci C, Chaoul N, et al. High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrology, dialysis, transplantation. 2021 Feb 20,;36(3):452–464.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Zhu L, Shi S, et al. Increased april expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore). 2016 Mar;95(11):e3099.
   PubMed Web of Science ®Google Scholar
• McCarthy DD, Chiu S, Gao Y, et al. BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of LIGHT. Cell Immunol. 2006 Jun;241(2):85–94.
   PubMed Web of Science ®Google Scholar
• Myette JR, Kano T, Suzuki H, et al. A proliferation inducing ligand (April) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019 07; 96(1): 104–116.
   PubMed Web of Science ®Google Scholar
• Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2017;11:747–757.
   PubMed Web of Science ®Google Scholar
• Huang SP, Snedecor SJ, Nanji S, et al. Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. Rheumatol Ther. 2022 May 21, 9(4):975–991.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17, 383(12):1117–1128.
   PubMed Web of Science ®Google Scholar
• Barrett C, Willcocks LC, Jones RB, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dialysis Transplantation. 2020 Apr 1, 35(4):599–606.
   PubMed Web of Science ®Google Scholar
• Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667–1675.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Jun;77(6):883–889.
   PubMed Web of Science ®Google Scholar
• Cogollo E, Cogollo E, Silva MA, et al. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (April-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006–2015.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012 Feb 7 14(1):R33.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018 Feb;70(2):266–276.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Steiner UC, Wuest B, et al. Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol. 2020;11:433.
   PubMed Web of Science ®Google Scholar
• Barratt J, Tumlin J, Suzuki Y, et al. Randomized Phase II JANUS study of atacicept in patients With IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022 May 26;7(8):1831–1841.
   Web of Science ®Google Scholar
• Dhillon S. Telitacicept: first Approval. Drugs. 2021 Aug 31,; 81(14):1671–1675.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao Q, Hou Y, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT‐18, a novel BLyS/April fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016 Jul;82(1):41–52.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Mathur M, Barratt J, et al. Mo258safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Vis649, An April-Neutralizing IGG2 Monoclonal Antibody, In Healthy Volunteers: Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study. Nephrology Dialysis Transplantation. 2021 May;36(Supplement_1):i205–i206.
   Google Scholar
• Barratt J, Hour B, Sibley C, et al. FC 040interim results of Phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of bion-1301 in patients with iga nephropathy. Nephrol Dialysis Transplantation. 2021 May;36(Supplement_1):i27–i28.
   PubMedGoogle Scholar
• Vignesh P, Rawat A, Sharma M, et al. Complement in autoimmune diseases. Clin Chim Acta. 2017 02;465:123–130.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiang L, Liu G, et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol. 2009 05; 69(5): 457–464.
   PubMed Web of Science ®Google Scholar
• Nam KH, Joo YS, Lee C, et al. Predictive value of mesangial C3 and C4d deposition in IgA nephropathy. Clin Immunol. 2020 February 1;211:108331.
   PubMed Web of Science ®Google Scholar
• Maeng Y, Kim M, Park J, et al. Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria. Int J Clin Exp Pathol. 2013;6(5):904–910.
   PubMed Web of Science ®Google Scholar
• Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Diseases. 1988 November 1; 12(5):348–352.
   PubMed Web of Science ®Google Scholar
• Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006 Jun;17(6):1724–1734.
   PubMed Web of Science ®Google Scholar
• Espinosa M, Ortega R, Sánchez M, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014 05; 9(5): 897–904.
   PubMed Web of Science ®Google Scholar
• Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol. 2009 Sep;68(3):318–319.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood. 2019 Feb 7, 133(6):540–549.
   PubMed Web of Science ®Google Scholar
• Rosenblad T, Rebetz J, Johansson M, et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol. 2014 Jun 13 29(11):2225–2228.
   PubMed Web of Science ®Google Scholar
• Ring T, Pedersen BB, Salkus G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J. 2015 Oct;8(5):489–491.
   PubMedGoogle Scholar
• Lafayette RA, Rovin BH, Reich HN, et al. Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney Int Rep. 2020 Nov;5(11):2032–2041.
   PubMed Web of Science ®Google Scholar
• Barratt J, Carroll K, Lafayette R. POS-107 long-term Phase 2 efficacy of the Masp-2 inhibitor narsoplimab for treatment of severe iga nephropathy. Kidney Int Rep. 2022 Feb;7(2):S45.
   Google Scholar
• Liu L, Zhang Y, Duan X, et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J Clin Immunol. 2014 Feb;34(2):224–232.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017 Sep;28(9):2756–2767.
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Nachman P, Parikh S, et al. TO012C5A receptor inhibitor avacopan in iga nephropathy study. Nephrology, dialysis, transplantation. 2017 May 1,;32(suppl_3):iii82.
   Google Scholar
• Hoy SM. Pegcetacoplan: first approval. Drugs. 2021 Aug 3; 81(12):1423–1430.
   PubMed Web of Science ®Google Scholar
• Gupta V, Bhavanasi S, Quadir M, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2018 Nov 29 13(3):319–330.
   PubMed Web of Science ®Google Scholar
• Bomback AS, Kavanagh D, Vivarelli M, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int Rep. 2022 Oct 1 7(10):2150–2159.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021 May;8(5):e344–e354.
   PubMed Web of Science ®Google Scholar
• Barratt J, Rovin B, Zhang H, et al. POS-546 efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled PHASE 2 study at 6 months. Kidney Int Rep. 2022 Feb;7(2):S236.
   Google Scholar
• Hendrickson DG, Hogan DJ, McCullough HL, et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol. 2009 Nov;7(11):e1000238.
   PubMed Web of Science ®Google Scholar
• Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018 Jun 1;28(3):19–118.
   Web of Science ®Google Scholar
• Janas MM, Harbison CE, Perry VK, et al. The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies. Toxicol Pathol. 2018 Oct;46(7):735–745.
   PubMed Web of Science ®Google Scholar
• Kim MJ, McDaid JP, McAdoo SP, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol. 2012 Oct 01, 189(7):3751–3758.
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Bhangal G, Page T, et al. Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int. 2015 Jul;88(1):52–60.
   PubMed Web of Science ®Google Scholar
• Kunwar S, Devkota AR, Ghimire DKC. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Rheumatol Int. 2016 Apr 25; 36(8):1077–1087.
   PubMed Web of Science ®Google Scholar
• Kang Y, Jiang X, Qin D, et al. Efficacy and safety of multiple dosages of fostamatinib in adult patients with rheumatoid arthritis: a systematic review and meta-analysis. Front Pharmacol. 2019;10:897.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec 1;319(3):998–1008.
   PubMed Web of Science ®Google Scholar
• Baluom M, Grossbard EB, Mant T, et al. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol. 2013 Jul;76(1):78–88.
   PubMed Web of Science ®Google Scholar
• F TWK, Tumlin J, Barratt J, et al. SUN-036 spleen tyrosine kinase (syk) inhibition in iga nephropathy: a global, Phase II, randomised placebo-controlled trial of fostamatinib. Kidney Int Rep. 2019 Jul;4(7):S168.
   PubMedGoogle Scholar
• Simonson MS, Shiang WANN, Mene P, et al. Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest. 1989;83(2):708–712.
   PubMed Web of Science ®Google Scholar
• Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 1991 Feb;39(2):307–311.
   PubMed Web of Science ®Google Scholar
• Chen HC, Guh JY, Chang JM, et al. Differential effects of FMLP-activated neutrophils from patients with IgA nephropathy enhanced endothelin 1 production of glomerular mesangial cells. Nephron. 2001;89(3):274–279.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ebihara I, Shirato I, et al. Endothelin-1 mRNA expression by peripheral blood monocytes in IgA nephropathy. Lancet. 1993 Nov 6;342(8880):1147–1148. (British edition).
   PubMed Web of Science ®Google Scholar
• Maixnerová D, Merta M, Reiterová J, et al. The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy. Folia Biol (Praha). 2007;53(1):27–32.
   PubMed Web of Science ®Google Scholar
• Tycová I, Hrubá P, Maixnerová D, et al. Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. Physiol Res. 2018 Mar 16, 67(1):93–105.
   PubMed Web of Science ®Google Scholar
• Lehrke I, WALDHERR R, Ritz E, et al. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12(11):2321–2329.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ebihara I, Fukui M, et al. Effect of a specific endothelin receptor a antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron. 1996;72(3):454–460.
   PubMed Web of Science ®Google Scholar
• Trachtman H, Nelson P, Adler S, et al. DUET: a Phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018 Nov;29(11):2745–2754.
   PubMed Web of Science ®Google Scholar
• Komers R, Diva U, Inrig JK, et al. Study design of the Phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020 Apr;5(4):494–502.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Santos J, Fraenkel M, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 May 11,;393(10184):1937–1947. (British edition).
   PubMed Web of Science ®Google Scholar
• Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009;20(3):655–664.
   PubMed Web of Science ®Google Scholar
• Kim S, Vo N, Lee S, et al. FC052: atrasentan for the treatment of IGA nephropathy: interim results from the affinity study. Nephrology, dialysis, transplantation. 2022 May;37:(Supplement_3).
   Google Scholar
• Kanai Y, WEN-SEN LEE, Guofeng YOU, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest. 1994;93(1):397–404.
   PubMed Web of Science ®Google Scholar
• Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022 Mar 26, 23(7):3651.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8, 383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 07; 100(1): 215–224.
   PubMed Web of Science ®Google Scholar
• Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 2021 07;100(1):24–26.
   PubMed Web of Science ®Google Scholar
• Collaborative Group EK, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease N Engl J Med. 2022 Nov 4.
   Web of Science ®Google Scholar
• Herrington WG, Wanner C, Green JB. The EMPA-KIDNEY collaborative group. design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrology, dialysis, transplantation, 2022 Mar 3,;37(7):1317–1329.
   PubMed Web of Science ®Google Scholar
• Baigent C, Emberson J, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 19;400(10365):1788–1801. (British edition).
   PubMedGoogle Scholar
• Yellin MJ, D’Agati V, Parkinson G, et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheumatism. 1997 Jan;40(1):124–134.
   PubMedGoogle Scholar
• Zhang DW, Qiu H, Mei YM, et al. repair effects of umbilical cord mesenchymal stem cells on podocyte damage of IgA nephropathy. J Biol Regul Homeost Agents. 2015 Jul;29(3):609–617.
   PubMed Web of Science ®Google Scholar
• Cueto I. ‘A golden age’: long neglected in medicine, rare kidney diseases see a surge in research. 2022; Available at: https://www.statnews.com/2022/08/23/rare-kidney-disease-research-igan/. Cited 8 August 2022.
   Google Scholar